Nuformix PLC Appointment of Non-Executive Director (2470G)
November 24 2020 - 2:00AM
UK Regulatory
TIDMNFX
RNS Number : 2470G
Nuformix PLC
24 November 2020
Nuformix plc
Appointment of Dr Julian Gilbert as Non-Executive Director
Cambridge, UK - 24 November 2020: Nuformix plc (LSE:NFX;
"Nuformix", the "Company" or the "Group"), a drug re-purposing
specialist, is pleased to announce the appointment of Dr Julian
Gilbert to the Board of Nuformix as a Non-Executive Director with
immediate effect.
Julian has more than 30 years of commercial and technical
experience in the pharmaceutical industry gained at a number of
companies including Chiroscience Plc, Mundipharma International
Limited, British Technology Group plc (BTG) and Smith Kline &
French (now GlaxoSmithKline plc). Most recently, Julian was
co-founder and CEO of Acacia Pharma Group plc (Acacia), raising
c.GBP100m in private and public funding and leading its flotation
on Euronext in 2018. Julian resigned from Acacia on 31 July 2019.
Prior to Acacia, he was co-founder and Commercial Director of
Arakis Limited which was sold to Sosei in 2005 for GBP107 million.
Julian has worked in business development since 1992 and has led
multiple business development projects.
Julian has a degree in pharmacy and a PhD in pharmaceutics, both
from the University of Nottingham.
Julian will be appointed as a member of the Nomination &
Audit Committees.
The Board is also undertaking a search for an additional
independent Non-Executive Director with recent and relevant
financial experience.
Dr Chris Blackwell, Executive Chairman, commented:
"It's a pleasure for us to welcome Julian to the Board. Julian's
knowledge and experience will be extremely valuable as the Company
moves forward with its near-term strategic priorities focussed on
business development and licensing opportunities. "
Commenting on his appointment, Dr Julian Gilbert said:
"I am delighted to be joining the Board of Nuformix, and look
forward to supporting the Company achieve key strategic
objectives."
No further information is required to be disclosed pursuant to
LR 9.6.13 R.
The person responsible for arranging the release of this
announcement on behalf of the Company is Dr Chris Blackwell,
Executive Chairman.
Enquiries:
Nuformix plc
Dr Chris Blackwell, Executive Chairman
Fleur Wood, Investor Relations
Email: fleur.wood@nuformix.com +44 (0)1223 627222
Novum Securities Limited
Jon Belliss / Colin Rowbury +44 (0)20 7399 9427
About Nuformix
Nuformix is a pharmaceutical development company focused on
unlocking the therapeutic potential and value of known drugs to
develop new novel medicines which provide therapeutic and
commercial advantages to the currently available drug form.
Nuformix's model of repurposing drugs utilises many technologies
but is focussed on its acknowledged expertise in the use of
cocrystal technology through which the Group has developed and
patented novel forms of small molecules. Its platform is not
therapy-specific but instead has broad application across a wide
range of indications. Using its technology, the Group is developing
proprietary medicines for its own development pipeline and in
partnership with pharmaceutical and biotech companies.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX. For more information please
visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEAEFDASFEFAA
(END) Dow Jones Newswires
November 24, 2020 02:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024